Catheter ablation of atrial fibrillation in heart failure with reduced ejection fraction

Nav Malhi1, Nathaniel M Hawkins1, Jason G Andrade1

  • 1Heart Rhythm Services, Division of Cardiology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada.

Insights

Catheter ablation is being explored for atrial fibrillation in heart failure patients with reduced ejection fraction. This review examines its effectiveness and safety for improving outcomes.

Area of Science:

  • Cardiology
  • Electrophysiology
  • Heart Failure Research

Background:

  • Atrial fibrillation and heart failure frequently coexist and are rising in prevalence.
  • Current treatments like rate control and pharmacologic rhythm control show no clear superiority in heart failure patients.
  • Antiarrhythmic drugs carry risks and limited efficacy in this population.

Purpose of the Study:

  • To review current evidence on catheter ablation for atrial fibrillation in patients with heart failure with reduced ejection fraction (HFrEF).
  • To assess patient selection criteria, efficacy, and safety of the procedure.
  • To evaluate the impact of catheter ablation on clinical outcomes in this specific patient group.

Main Methods:

  • Systematic review of contemporary studies.
  • Analysis of data on patient selection, ablation techniques, and outcomes.
  • Evaluation of safety profiles and adverse events associated with catheter ablation.

Main Results:

  • Evidence suggests catheter ablation may be a viable option for select HFrEF patients with atrial fibrillation.
  • Studies indicate potential benefits in improving ejection fraction and quality of life.
  • Safety data is still evolving, but the procedure appears feasible with acceptable risks when performed by experienced centers.

Conclusions:

  • Catheter ablation warrants consideration as a treatment strategy for atrial fibrillation in HFrEF patients.
  • Further research is needed to optimize patient selection and long-term outcomes.
  • This approach may offer an alternative to less effective pharmacologic therapies.

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.0K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.0K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
951
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
395
Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
12.0K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.0K